Already a Bloomberg.com user?
Sign in with the same account.
Don't have an account?
Help! I can't access my account.
"Make-or-Break Time for Cancer Drugs" (Personal Business, June 8, 2009) mistakenly said that biotech company Celgene has a forthcoming treatment for hepatitis C. Celgene is not focusing on this disease.
Max 250 characters
©2013 Bloomberg L.P. All Rights Reserved. Made in NYC